Search results
Showing results for
This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.
©
Curt Carnemark, World Bank
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
